Memorial Hospital Research Laboratories

The Luis Diaz Jr. Lab

Share
Back to top

Research

Dr. Luis Alberto Diaz, Jr.
Luis Diaz Jr., MD
Head of the Division of Solid Tumor Oncology; Grayer Family Chair

Our team is focused on developing novel tools and approaches for the diagnosis and treatment of cancer using genomics as a guide.

Lab Members

Featured News

Rectal Cancer Disappears After Experimental Use of Immunotherapy
Rectal Cancer Disappears After Experimental Use of Immunotherapy
Rectal cancer patients saw their tumors disappear in a clinical trial involving immunotherapy at Memorial Sloan Kettering Cancer Center—without surgery, radiation, or chemotherapy.

Publications Highlights

PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer
Cercek A, Lumish M, Sinopoli J, Weiss J,..,Diaz LA Jr.. N Engl J Med. 2022 Jun 23;386(25):2363-2376. doi: 10.1056/NEJMoa2201445. Epub 2022 Jun 5. PMID: 35660797, PMCID: PMC9492301.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le DT, Uram JN, Wang H,…,Diaz LA Jr.. N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30. PMID: 26028255; PMCID: PMC4481136.

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, Piha-Paul SA, Doi T, Gao B, Chung HC, Lopez-Martin J, Bang YJ, Frommer RS, Shah M, Ghori R, Joe AK, Pruitt SK, Diaz LA Jr.

Cancer genome landscapes.
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW.Science. 2013 Mar 29;339(6127):1546-58. doi: 10.1126/science.1235122.

Immunotherapy in colorectal cancer: rationale, challenges and potential.
Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, Diaz LA Jr.

View All Publications

People

Dr. Luis Alberto Diaz, Jr.

Luis Diaz Jr., MD

Head of the Division of Solid Tumor Oncology; Grayer Family Chair

  • Our team is focused on developing novel tools and approaches for the diagnosis and treatment of cancer using genomics as a guide.
  • MD, University of Michigan
[email protected]
Email Address
646-888-4641
Office Phone
View physician profile
Physician profile

Members

Somer Abdelfattah

Sr. Research Technician

Guillermo Argiles Martinez

Sr. Research Scientist

Oliver Artz

Bioinformatics software engineer-I

Andrea Cercek

Associate Attending

Michael Foote

Assistant Attending

Justin Haseltine

Assistant Attending

Rachel Hughes Rodriguez

Fellow

Paul Johannet

Assistant Attending

Steven Maron

Assistant Attending

Nathalie Membreno

Research Technician

David Mieles

Research Technician

Miteshkumar Patel

Research Laboratory Manager

Violaine Randrian

Visiting Investigator

Karthik Rangavajhula
Benoît Camelli-Rousseau
Benoît Rousseau

Assistant Attending

Georgios Vlachos

Gradaute Research Assistant

Callahan Wilde

Research Project Associate

Lab Alumni
Joana Vidal Barrull
Joana Vidal Barrull

Visiting Investigator

Erika Gedvilaite, MS
Erika Gedvilaite

Senior Laboratory Technician

Drew Gerber

Research Technician

Michelle Lamendola-Essel
Michelle Lamendola-Essel

Project Portfolio Manager, Sr.

Sonya Li
Sonya Li

Senior Staff Scientist

Lingqi Luo

Bioinformatics Engineer II

Shrey Patel

Research Technician

Caitlin Stewart

Research Scientist

Jonathan C. M. Wan

Visiting Investigator & MD Candidate

Lab Affiliations

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Luis Diaz Jr. discloses the following relationships and financial interests:

  • ChromaCode
    Equity
  • Delfi Diagnostics, Inc.
    Equity; Professional Services and Activities (Uncompensated)
  • Epitope
    Equity; Fiduciary Role / Position
  • Innovatus Capital Partners, LLC
    Professional Services and Activities
  • Johns Hopkins University School of Medicine
    Intellectual Property Rights
  • Neophore
    Equity; Professional Services and Activities (Uncompensated)
  • Quest Diagnostics
    Equity; Fiduciary Role / Position
  • Seer Biosciences
    Equity; Professional Services and Activities
  • Zydecom
    Equity

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures